Asthma treatment

21. (Walnut Creek, CA) – January 18, 2000 ADVERTISING SURGE HAS PATIENTS REQUESTING MEDICINE BY NAME, SOME DOCTORS WORRY SUPERFICIAL INFORMATION PROMPTS SELF-DIAGNOSING, BUT OTHERS FEEL IT HELPS PEOPLE RECOGNIZE SYMPTOMS Allegra, Claritin, Zyrtec, Zyban, Accolate, Zomig. These once strange-sounding names are now common, with the stream of advertisements promoting prescription drugs by name and the Internet offering easy access to information. This can have its good points and bad, physicians say. From patients coming into doctors’ offices and asking for a particular drug by name to being frightened of a drug because of possible and sometimes scary side effects, doctors see it all ….. . Independent, The (London, England)/Financial Times – July 21, 1998 The Independent: Zeneca launches asthma tablet THE PHARMACEUTICAL giant Zeneca yesterday officially launched a new tablet that could replace inhalers used by some of Britain’s three million asthma sufferers. The group said its new Accolate anti-asthma tablet was the first new treatment of its kind in the UK and the first alternative to inhaled steroids for 20 years. Accolate is one of a new class of drugs known as LTRAs, which block the effects that trigger inflammation and mucus secretion and cause constriction in the ….. – January 14, 2009 FDA: No suicide risk associated with Merck drug Merck’s asthma medicine Singulair and related treatments weren’t associated with an increased risk of suicide or suicidal urges, U. S. regulators said after a review of clinical trials. The Food and Drug Administration, in the updated safety review posted yesterday on its website, said it is still assessing data on other psychiatric side effects of montelukast, Singulair’s chemical name, along with AstraZeneca’s Accolate and Cornerstone ….. Evening Standard, The (London, England) – July 20, 1998 Evening Standard: Business Day: Zeneca’s tablets lift for asthma sufferers ASTHMA sufferers will now be able to take treatment in tablet form rather than via inhaler, following today’s launch by Zeneca of its new Accolate drug, writes Fiona Walsh. For mild to moderate asthma sufferers, who make up the vast majority of Britain’s three million patients, this is the first alternative to inhaled steroids to be introduced for 20 years. Zeneca said the tablet form of the drug ‘may be an important factor’ in its ….. Daily Mail, The (London, England) – September 21, 1999 Daily Mail: JAB FOR DRUG FIRMS AS BUYERS PERK UP DRUG shares are looking much healthier. Buyers are sniffing around again, attracted to the defensive and growth merits of the sector which comes into its own when cyclicals disappoint. There is also the continued prospect of further consolidation in a global industry where the larger players each control under 5pc of the market, Astra Zeneca zoomed 58p to 2558p for a two-day jump of 115p. Accolate, its novel mini-tablet treatment of asthma, has been approved by the US Food ….&. Financial Times (London, England) – March 30, 1996 Companies and Finance: Zeneca shrugs off rejection of Accolate by FDA Chemicals, Chemicals-Commodity. Zeneca, the UK drugs company, yesterday fought back against the rejection of its asthma drug Accolate by advisers to the US Food and Drug Administration. The company described the series of votes by FDA advisers on Thursday as ‘conditional approval’ even though it lost the vote on the drug’s ‘approvability’ by six votes to three. Votes on the drug’s efficacy went in the ….. Record, The (Kitchner, Ontario, Canada) – November 15, 1997 New pill helps asthmatics breathe easy The first new class of asthma drugs in Canada in 20 years has been introduced in time for the cold weather that’s especially hard on people with the chronic lung disease. Accolate is the only pill-form anti-inflammatory available here that helps mild to moderate asthmatics breathe easier. It was recently approved by Health Canada after clinical trials involving 4, 000 patients worldwide, researchers said Thursday. “This medical advance places us on a threshold of ….. Newstex Blogs (USA) – June 15, 2009 New Precautions on Asthma Meds Jun. 15, 2009 ( b5media delivered by Newstex) The FDA has requested that a new precaution be added to the drug prescribing information for some popular asthma medications. The medicines are known as leukotriene modifiers and include • Singulair (montelukast) • Accolate (zafirlukast) • Zyflo and Zyflo CR (zileuton) According to the FDA, neuropsychiatric events have been reported in some ….. New York Times, The (NY) – October 19, 1999 Perseverance Is Key to a Good Life With Asthma Until about three years ago, Dawn Bosquez, a 30-year-old resident of Denver, was getting most of her medical care for asthma in emergency rooms. About once a month, she would wake up unable to breathe and would frantically call an ambulance or friend to rush her to the hospital, where she would be given oxygen and inhaled medications to bring the attack under control. Then, a doctor would prescribe a short course or “burst” of prednisone tablets, a powerful ….. Financial Express (India) – July 9, 2008 Financial Express: AstraZeneca sues DRL over Accolate The United States, the largest pharmaceuticals market in the globe, still lures Indian generic firms to grab a pie of the patent protected drugs through the litigation route. In the latest incident, Dr Reddy’s Labs (DRL) has been sued by US major, AstraZeneca, following DRL’s paragraph IV abbreviated new drug application (ANDA) submission for marketing Accolate, the US firms’ leading drug used to treat asthma. In a suit filed on June 27 in the district court ….